Results 151 to 160 of about 358,537 (259)

A neuropsychological perspective on sensory hypersensitivity after acquired brain injury. [PDF]

open access: yesBrain Commun
Heijman JO   +8 more
europepmc   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen   +13 more
wiley   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller   +9 more
wiley   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest   +4 more
wiley   +1 more source

Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness

open access: yes, 2019
Mohammed G Turkmani,1 Koenraad De Boulle,2 Wolfgang G Philipp-Dormston31Derma Clinic, Riyadh, Saudi Arabia; 2Aalst Dermatology Clinic, Aalst, Belgium; 3Cologne Dermatology, Cologne, GermanyBackground: Delayed reactions after facial hyaluronic acid ...
Philipp-Dormston WG   +2 more
core  

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem   +5 more
wiley   +1 more source

Gabapentinoids‐duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy